Vinod Ravi

6.5k total citations
144 papers, 3.0k citations indexed

About

Vinod Ravi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Vinod Ravi has authored 144 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Pulmonary and Respiratory Medicine, 80 papers in Oncology and 46 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Vinod Ravi's work include Sarcoma Diagnosis and Treatment (76 papers), Vascular Tumors and Angiosarcomas (58 papers) and Cardiac tumors and thrombi (45 papers). Vinod Ravi is often cited by papers focused on Sarcoma Diagnosis and Treatment (76 papers), Vascular Tumors and Angiosarcomas (58 papers) and Cardiac tumors and thrombi (45 papers). Vinod Ravi collaborates with scholars based in United States, India and United Kingdom. Vinod Ravi's co-authors include Dejka M. Araujo, Robert S. Benjamin, Wei‐Lien Wang, Alexander J. Lazar, Shreyaskumar Patel, Anthony P. Conley, B. Ashleigh Guadagnolo, Neeta Somaiah, Dina Lev and Keila E. Torres and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Vinod Ravi

131 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vinod Ravi United States 30 1.7k 1.6k 1.0k 464 416 144 3.0k
Antonio López–Pousa Spain 32 1.9k 1.1× 1.7k 1.1× 448 0.4× 804 1.7× 273 0.7× 161 3.4k
Federica Grosso Italy 33 3.0k 1.8× 1.8k 1.2× 621 0.6× 535 1.2× 418 1.0× 158 4.4k
Beatrice Seddon United Kingdom 29 2.4k 1.5× 1.2k 0.8× 622 0.6× 662 1.4× 280 0.7× 74 3.4k
Mark Agulnik United States 36 2.1k 1.2× 2.6k 1.7× 620 0.6× 782 1.7× 397 1.0× 165 4.2k
Charlotte Benson United Kingdom 31 2.1k 1.2× 1.4k 0.9× 524 0.5× 422 0.9× 187 0.4× 127 3.1k
Alessandro Comandone Italy 25 2.3k 1.4× 1.4k 0.9× 539 0.5× 621 1.3× 237 0.6× 103 3.0k
Jackie Szymonifka United States 37 1.0k 0.6× 1.2k 0.8× 793 0.8× 711 1.5× 322 0.8× 115 4.1k
Arthur P. Staddon United States 29 2.4k 1.5× 1.4k 0.9× 482 0.5× 318 0.7× 255 0.6× 67 3.5k
Augustinus D. G. Krol Netherlands 28 2.2k 1.3× 1.0k 0.6× 768 0.8× 354 0.8× 284 0.7× 77 4.5k
Palma Dileo United Kingdom 18 1.6k 1.0× 850 0.5× 445 0.4× 243 0.5× 193 0.5× 52 2.0k

Countries citing papers authored by Vinod Ravi

Since Specialization
Citations

This map shows the geographic impact of Vinod Ravi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vinod Ravi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vinod Ravi more than expected).

Fields of papers citing papers by Vinod Ravi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vinod Ravi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vinod Ravi. The network helps show where Vinod Ravi may publish in the future.

Co-authorship network of co-authors of Vinod Ravi

This figure shows the co-authorship network connecting the top 25 collaborators of Vinod Ravi. A scholar is included among the top collaborators of Vinod Ravi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vinod Ravi. Vinod Ravi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ravi, Vinod, et al.. (2024). MANEUVER: A Phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patients. Future Oncology. 22(5). 507–514. 7 indexed citations
2.
Wagner, Andrew J., Vinod Ravi, Richard F. Riedel, et al.. (2024). Phase II Trial of nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update. Journal of Clinical Oncology. 42(13). 1472–1476. 16 indexed citations
3.
Chiang, Yi‐Ju, Anthony P. Conley, Dejka M. Araujo, et al.. (2024). Systemic therapy in NF-1 associated malignant peripheral nerve sheath tumors (MPNST).. Journal of Clinical Oncology. 42(16_suppl). 11583–11583. 1 indexed citations
4.
5.
Brockstein, Bruce, et al.. (2024). Adult-onset multifocal kaposiform hemangioendothelioma in the bone marrow, lung, liver, and brain: a case report. Frontiers in Oncology. 14. 1322684–1322684.
6.
Khawaja, Fareed, Adina L. Feldman, Vinod Ravi, et al.. (2023). COVID‐19 in cancer patients: The impact of vaccination on outcomes early in the pandemic. Cancer Medicine. 12(24). 22006–22022. 5 indexed citations
7.
Farooqi, Ahsan, Vinod Ravi, Ryan P. Goepfert, et al.. (2023). Outcomes after definitive treatment for cutaneous angiosarcomas of the face and scalp: Reevaluating the role of surgery and radiation therapy. Head & Neck. 45(8). 1943–1951. 4 indexed citations
8.
Ravi, Vinod, Scott M. Schuetze, Sujana Movva, et al.. (2022). OER‐073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma. Cancer. 128(19). 3516–3522. 12 indexed citations
9.
Subbiah, Vivek, Pete Anderson, Kalevi Kairemo, et al.. (2019). Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clinical Cancer Research. 25(13). 3802–3810. 32 indexed citations
10.
Francis, Ashleigh M., Angela Alexander, Yanna Liu, et al.. (2017). CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. Molecular Cancer Therapeutics. 16(9). 1751–1764. 41 indexed citations
11.
Groisberg, Roman, Ken Hess, Siqing Fu, et al.. (2017). Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Scientific Reports. 7(1). 15963–15963. 21 indexed citations
12.
Schvartsman, Gustavo, Michael J. Wagner, Behrang Amini, et al.. (2017). Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. Scientific Reports. 7(1). 9519–9519. 17 indexed citations
13.
Saleh, Walid K. Abu, Basel Ramlawi, Oz M. Shapira, et al.. (2017). Improved Outcomes With the Evolution of a Neoadjuvant Chemotherapy Approach to Right Heart Sarcoma. The Annals of Thoracic Surgery. 104(1). 90–96. 75 indexed citations
14.
Ravi, Vinod, Pandurangan Vijayanand, Noor Ahmad Shaik, et al.. (2015). Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study. Asian Pacific Journal of Cancer Prevention. 16(16). 7071–7076. 6 indexed citations
15.
Joseph, Jason, Wei‐Lien Wang, Madhavi Patnana, et al.. (2015). Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma. PubMed. 5(1). 22–22. 33 indexed citations
16.
Satelli, Arun, Abhisek Mitra, Jeffry J. Cutrera, et al.. (2014). Universal Marker and Detection Tool for Human Sarcoma Circulating Tumor Cells. Cancer Research. 74(6). 1645–1650. 131 indexed citations
17.
Ravi, Vinod, et al.. (2014). IgA dominant poststaphylococcal glomerulonephritis: Complete recovery with steroid therapy. Indian Journal of Nephrology. 24(5). 336–336. 3 indexed citations
18.
Conter, Henry Jacob, Vancheswaran Gopalakrishnan, Vinod Ravi, et al.. (2014). Adult versus Pediatric Neuroblastoma: The M.D. Anderson Cancer Center Experience. Sarcoma. 2014. 1–6. 24 indexed citations
19.
Ravi, Vinod & Shreyaskumar Patel. (2013). Vascular Sarcomas. Current Oncology Reports. 15(4). 347–355. 38 indexed citations
20.
Raj, Sean D., Xiao Zhou, Carlos E. Bueso‐Ramos, et al.. (2011). Prognostic Significance of Elevated D-Dimer for Survival in Patients with Sarcoma. American Journal of Clinical Oncology. 35(5). 462–467. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Antonio López–Pousa Breakdown of academic impact, for papers by Federica Grosso Breakdown of academic impact, for papers by Beatrice Seddon Breakdown of academic impact, for papers by Mark Agulnik Breakdown of academic impact, for papers by Charlotte Benson Breakdown of academic impact, for papers by Alessandro Comandone Breakdown of academic impact, for papers by Jackie Szymonifka Breakdown of academic impact, for papers by Arthur P. Staddon Breakdown of academic impact, for papers by Augustinus D. G. Krol Breakdown of academic impact, for papers by Palma Dileo
Rankless by CCL
2026